Vernalis Licenses its Lead Compound for Parkinson’s disease to Biogen Idec
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 50 (Table of Contents)
Published: 4 Aug-2004
DOI: 10.3833/pdr.v2004.i50.788 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Vernalis entered into an exclusive worldwide licensing deal with Biogen to develop and commercialise its lead compound V2006 for treating Parkinson’s disease and other CNS disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS